Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerUrate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancerThe tumor lysis syndromeAntitumor activity of a pyrrole-imidazole polyamideAcute kidney injury in critically ill cancer patients: an updateAcute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies)Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesPrevention and management of tumor lysis syndrome in adults with malignancyA focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologistRasburicase in the management of tumor lysis: an evidence-based review of its place in therapyA review in the treatment of oncologic emergencies.Carfilzomib-associated tumor lysis syndrome.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesSpontaneous Tumor Lysis Syndrome in a Patient with Metastatic Small Cell Lung Cancer: A Case ReportSpontaneous tumor lysis syndrome in the setting of B-cell lymphoma.Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndromeAssociation of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals.What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literatureRisk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceTumor Lysis Syndrome in a Retroperitoneal Sarcoma.Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III studyRasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group ReportTumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the LiteraturePrevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.Tumor lysis and acute renal failure in Burkitt's lymphoma: A review on pathophysiology and management.Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood.
P2860
Q24194387-271F70BB-EB6A-44A0-AD61-A9BB7B800523Q24234902-9C436649-D173-4D08-9261-D267013B9FCCQ24605151-238EEDC7-4F15-434F-8C3C-11C2A096C1BAQ24628320-A40961E2-8918-4616-B7AA-0B4B6524397AQ26740168-4F56BC41-7751-47E1-A654-4511DA60319DQ26745670-7C87DEFA-C333-4962-9F23-8C80038C5797Q26862904-ADBB4BFD-BA80-4E42-9BD9-CBE7E14095F0Q27003152-84ABBCF2-ECC8-4B11-AA84-BFB5A9ACFA3BQ27012513-7C54610D-A8B7-433F-BFA6-7BFDC122F359Q28082089-FA88DDDB-B700-45E6-BD7D-A6D65E4A6F4EQ30252082-B430A226-F4DC-4E39-B827-384470A2BA47Q33412480-49C14308-EA2F-4A72-8B85-23AFA969EEDDQ33423873-5EE887AE-CED8-4689-8FED-38493DA3A07FQ33701703-4256FB3C-07CF-4D89-B17E-482D8CC8D20AQ33719237-EC2B1DB9-8BE9-4A7B-AF11-1C20FEDB84A6Q33758537-AC81DC41-A56D-4BB5-A27D-2CC7281B5093Q33947841-351C46E1-5AE3-466E-9067-31899B5B8B23Q34141630-2D27FFA8-0879-4D6B-957C-5A6C5D705FCDQ34434989-46B17C10-5AF1-4174-9386-FEF5098E681FQ34459365-7F77D4B4-A259-4777-A95C-6E1AC39BDDCAQ35136271-694D3D4C-1968-46E8-BBF0-C79470081890Q35182162-9F90F6EB-7839-46A5-B889-DE422C7A925FQ35683889-777F1B3E-7EC9-439D-897B-FEDCB343C54AQ35742173-C189F2F7-47E0-4D27-959D-EDEED61ED616Q35927686-E3FD6952-8349-45F2-859E-DB8B804A79BEQ36036576-DCFD33E3-9362-434A-9041-914AB7CCD9F8Q36204470-5348538B-1DC9-4E4C-B4B9-9A4C13834ACEQ36629257-A76B4970-F5D4-479E-AD23-93FCECE59F69Q36801616-CCAB1183-7508-44D2-A431-EBE5E135D012Q36929831-22AE7790-6805-4AEA-9F6A-D5C70EDD993DQ37015136-0CD1EB39-5331-4AEA-9F22-FC335A5ED8FFQ37163858-85A177B0-0791-4F00-87E8-4093414067FCQ37329442-F20B58CE-C709-4A81-A7C4-4E3EB23B8207Q37414397-B4AE24F8-047B-4111-BDEC-813E4B9FA2A5Q37629599-5F3D3D62-472F-4391-89FA-1EE6E8D2D803Q37634744-A0FF6283-C51F-4DCD-8CD4-62D254C1A7A9Q37717853-8E7D5C9F-DBA8-4A43-94F5-D65A76499ABFQ37740958-43D5D3C9-B5AC-4134-8A2D-DB21D39164FBQ37788882-26BFF004-BF9C-45C1-B801-88DC26FFF747Q37831902-2133C7B1-D2DB-44A1-8884-B4CD9A2675F6
P2860
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Guidelines for the management ...... ome: an evidence-based review.
@en
Guidelines for the management ...... ome: an evidence-based review.
@nl
type
label
Guidelines for the management ...... ome: an evidence-based review.
@en
Guidelines for the management ...... ome: an evidence-based review.
@nl
prefLabel
Guidelines for the management ...... ome: an evidence-based review.
@en
Guidelines for the management ...... ome: an evidence-based review.
@nl
P2093
P356
P1476
Guidelines for the management ...... ome: an evidence-based review.
@en
P2093
Anas Younes
Arnold Altman
Bertrand Coiffier
Ching-Hon Pui
Mitchell S Cairo
P304
P356
10.1200/JCO.2007.15.0177
P407
P577
2008-06-01T00:00:00Z